Abstract 3449
Background
Early intracranial progression (ICP) reduce the efficacy of first line radiosurgery (SRS) for brain metastases. We aim to develop and validate a MR imaging-derived radiomic signature (RS) via deep learning approach for the prediction of 1-year disseminated ICP (DICP; more than or equal to 3 lesions and leptomeningeal carcinomatosis) in brain metastases patients treated with SRS.
Methods
A total of 1304 MRI-based radiomic features of pretreatment tumors were obtained from 208 patients with 451 lesions, who received first line SRS during August 2008 to January 2018. Variational autoencoder (VAE), trained with symmetric two encoded and decoded layers of neural network and 1,649,560 trainable parameters, was applied to reduce the dimensionality of radiomc features to 128 VAE-radiomic features. Penalized regression with 10-fold cross validation using least absolute shrinkage and selection operator performs features selection and construct RS to predict 1-year DICP events in train set of 150 patients, which was validated in test set of 58 patients. Harrell’s C-index was used to evaluate the discriminative ability of RS in both sets. The correlation of VAE-radiomic features and molecular features was analyzed by student t-test. Survival analysis was calculated using the Kaplan-Meier method.
Results
The RS yielded 1000 times bootstrapping corrected C-index of 0.746 and 0.747 for discrimination of 1-year DICP in the train and test cohorts, respectively. As for the subgroup of patients with lung (n = 175) and breast (n = 23) origin, the RS also showed good predictive performance with C-indices of 0.735 and 0.755, respectively. EGFR-mutation (n = 113) and ER (n = 22) status were associated with selected VAE-radiomic features No. 98 (p = 0.035) and No.127 (p = 0.44), respectively. Dichotomized risk category using RS of -0.769 (Youden index) as cut-off point yielded median overall survival of 57.7 months in low risk compared to 20.5 months in high risk group (p < 0.01).
Conclusions
The RS model provides a novel approach to predict 1-year DICP and survival in brain metastases receiving SRS, and is warranted to be integrated into GPA for optimal selection of patients treated with first line SRS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1842 - Immunological impact of surgery in NSCLC patients
Presenter: Akitoshi Yanagihara
Session: Poster Display session 1
Resources:
Abstract
4124 - The prognostic value of selected immunological panel in predicting the prognosis of early-stage resectable non-small cell lung cancer
Presenter: Sha Zhao
Session: Poster Display session 1
Resources:
Abstract
4468 - Genomic Heterogeneity and Clonality Analysis of Multiple synchronous lung cancers (MSLCs)
Presenter: Fachen Zhou
Session: Poster Display session 1
Resources:
Abstract
5547 - Analysis of immunosuppressive factors produced by tumorspheres in NSCLC. Prognostic value of Galectin-3 in adenocarcinoma
Presenter: Susana Torres Martinez
Session: Poster Display session 1
Resources:
Abstract
1658 - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small-cell lung cancer (NSCLC) after complete tumour resection
Presenter: Masahiro Tsuboi
Session: Poster Display session 1
Resources:
Abstract
1535 - EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)
Presenter: Nussara Leeladejkul
Session: Poster Display session 1
Resources:
Abstract
3262 - Prognostic significance of elements of the adaptive immunity in the microenvironment of early-stage non small cell lung cancer
Presenter: Aliki Liakea
Session: Poster Display session 1
Resources:
Abstract
4643 - Combined immunoscore for prognostic stratification of early stage NSCLC patients
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4819 - Radiation-induced lung injury and misdiagnosis rate after SBRT
Presenter: Xiaolong Fu
Session: Poster Display session 1
Resources:
Abstract
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract